Не сдохни! Еда в борьбе за жизнь

^{‹‹14››.} Aitken M, Johns Hopkins Bloomberg School of Public Health. The trillion dollar market for medicines: characteristics, dynamics and outlook. http://www.jhsph.edu/research/centers-and-institutes/center-for-drug-safety-and-effectiveness/academic-training/seminar-series/MUrray%20Aikten.pdf. February 24, 2014. Accessed March 29, 2015.

^{‹‹15››.} Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296(5568):695–8.

^{‹‹16››.} Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296(5568):695–8.

^{‹‹17››.} Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol. 1977;39(2):239–43.

^{‹‹18››.} Mayo Clinic News Network. Nearly 7 in 10 Americans take prescription drugs, Mayo Clinic, Olmsted Medical Center Find. http://newsnetwork.mayoclinic.org/discussion/nearly-7-in-10-americans-take-prescription-drugs-mayo-clinic-olmsted-medical-center-find/. June 19, 2013. Accessed March 31, 2015.

^{‹‹19››.} Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.

^{‹‹20››.} Crimmins EM, Beltran-Sanchez H. Mortality and morbidity trends: is there compression of morbidity? J Gerontol B Psychol Sci Soc Sci. 2011;66(1):75–86.

^{‹‹21››.} Crimmins EM, Beltrán-Sánchez H. Mortality and morbidity trends: is there compression of morbidity? J Gerontol B Psychol Sci Soc Sci. 2011;66(1):75–86.

^{‹‹22››.} Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138–45.

^{‹‹23››.} Offord DR. Selection of levels of prevention. Addict Behav. 2000;25(6):833–42.

^{‹‹24››.} Gofrit ON, Shemer J, Leibovici D, Modan B, Shapira SC. Quaternary prevention: a new look at an old challenge. Isr Med Assoc J. 2000;2(7):498–500.

^{‹‹25››.} Strasser T. Reflections on cardiovascular diseases. Interdiscip Sci Rev. 1978;3(3):225–30.

^{‹‹26››.} Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.

^{‹‹27››.} Yancy CW. Is ideal cardiovascular health attainable? Circulation. 2011;123(8):835–7.

^{‹‹28››.} Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.

^{‹‹29››.} Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

^{‹‹30››.} Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.

^{‹‹31››.} Shay CM, Ning H, Allen NB, et al. Status of cardiovascular health in US adults: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003–2008. Circulation. 2012;125(1):45–56.

^{‹‹32››.} Shay CM, Ning H, Allen NB, et al. Status of cardiovascular health in US adults: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003–2008. Circulation. 2012;125(1):45–56.

^{‹‹33››.} Omran AR. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49(4):509–38.